日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial

白细胞介素 6 单克隆抗体治疗系统性红斑狼疮的疗效和安全性:一项 II 期剂量范围随机对照试验

Wallace, Daniel J; Strand, Vibeke; Merrill, Joan T; Popa, Serghei; Spindler, Alberto J; Eimon, Alicia; Petri, Michelle; Smolen, Josef S; Wajdula, Joseph; Christensen, Jared; Li, Cheryl; Diehl, Annette; Vincent, Michael S; Beebe, Jean; Healey, Paul; Sridharan, Sudhakar

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study

依那西普治疗早期非放射性中轴型脊柱关节炎的临床和MRI反应:EMBARK研究的48周结果

Maksymowych, Walter P; Dougados, Maxime; van der Heijde, Désirée; Sieper, Joachim; Braun, Jürgen; Citera, Gustavo; Van den Bosch, Filip; Logeart, Isabelle; Wajdula, Joseph; Jones, Heather; Marshall, Lisa; Bonin, Randi; Pedersen, Ron; Vlahos, Bonnie; Kotak, Sameer; Bukowski, Jack F

Pharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trials

依那西普单药治疗日本类风湿性关节炎患者的药代动力学、疗效和安全性:七项临床试验的回顾

Takeuchi, Tsutomu; Miyasaka, Nobuyuki; Kawai, Shinichi; Sugiyama, Naonobu; Yuasa, Hirotoshi; Yamashita, Noriaki; Sugiyama, Noriko; Wagerle, Lorin Craig; Vlahos, Bonnie; Wajdula, Joseph

Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study

CLIPPER 研究第 1 部分(第 12 周)研究评估了开放标签依那西普治疗扩展型少关节型幼年特发性关节炎、附着点炎相关性关节炎和银屑病关节炎的疗效和安全性。

Horneff, Gerd; Burgos-Vargas, Ruben; Constantin, Tamas; Foeldvari, Ivan; Vojinovic, Jelena; Chasnyk, Vyacheslav G; Dehoorne, Joke; Panaviene, Violeta; Susic, Gordana; Stanevica, Valda; Kobusinska, Katarzyna; Zuber, Zbigniew; Mouy, Richard; Rumba-Rozenfelde, Ingrida; Breda, Luciana; Dolezalova, Pavla; Job-Deslandre, Chantal; Wulffraat, Nico; Alvarez, Daniel; Zang, Chuanbo; Wajdula, Joseph; Woodworth, Deborah; Vlahos, Bonnie; Martini, Alberto; Ruperto, Nicolino

Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study

一项为期2年的双盲随机研究比较了依那西普联合柳氮磺胺吡啶与单用依那西普治疗类风湿性关节炎患者的疗效、安全性和患者报告结局。

Combe, B; Codreanu, C; Fiocco, U; Gaubitz, M; Geusens, P P; Kvien, T K; Pavelka, K; Sambrook, P N; Smolen, J S; Khandker, R; Singh, A; Wajdula, J; Fatenejad, S

Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison

依那西普和柳氮磺胺吡啶单药及联合用药治疗虽已接受柳氮磺胺吡啶治疗但仍处于活动期的类风湿关节炎患者:一项双盲对照研究

Combe, B; Codreanu, C; Fiocco, U; Gaubitz, M; Geusens, P P; Kvien, T K; Pavelka, K; Sambrook, P N; Smolen, J S; Wajdula, J; Fatenejad, S

A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs

一项长期、开放标签试验,旨在评估依那西普(恩利)在未接受其他改善病情抗风湿药物治疗的类风湿关节炎患者中的安全性和有效性。

Klareskog, L; Gaubitz, M; Rodriguez-Valverde, V; Malaise, M; Dougados, M; Wajdula, J

Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis

对于强直性脊柱炎患者,每周一次 50 毫克依那西普与每周两次 25 毫克依那西普疗效相当。

van der Heijde, D; Da Silva, J C; Dougados, M; Geher, P; van der Horst-Bruinsma, I; Juanola, X; Olivieri, I; Raeman, F; Settas, L; Sieper, J; Szechinski, J; Walker, D; Boussuge, M-P; Wajdula, J S; Paolozzi, L; Fatenejad, S